Used in the treatment of Parkinson’s disease, particularly as an add-on therapy to levodopa in patients experiencing motor fluctuations. It helps prolong the duration of symptom control by inhibiting the breakdown of dopamine through selective and reversible inhibition of monoamine oxidase B (MAO-B). Additionally, it exhibits glutamate release modulation, which may contribute to neuroprotective effects and help reduce motor symptoms without significantly increasing dyskinesia. Its dual mechanism supports improved motor function and quality of life in mid to late-stage Parkinson’s patients.